Vaccinex, Inc. (VCNX) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Vaccinex, Inc. (VCNX) trades at $1.10 with AI Score 55/100 (Grade B). Vaccinex, Inc. is a clinical-stage biotechnology company focused on developing targeted biotherapeutics for cancer, neurodegenerative diseases, and autoimmune disorders. Market cap: $2.94M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 15, 2026Analyst Coverage for VCNX: VCNX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates VCNX against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
VCNX: the 3 scored disciplines are evenly split. Dominant signal: Ken Griffin bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Vaccinex, Inc. (VCNX) Healthcare & Pipeline Overview
Vaccinex, Inc. is a clinical-stage biotechnology company specializing in targeted biotherapeutics for unmet medical needs, including pepinemab, a humanized monoclonal antibody in clinical trials for cancer and neurodegenerative diseases. The company operates in the competitive biotechnology sector, focusing on novel treatments for serious conditions.
What Is the Investment Thesis for VCNX?
Vaccinex, Inc. presents a high-risk, high-reward investment profile typical of clinical-stage biotechnology companies. The primary value driver is the successful development and commercialization of pepinemab, which targets a range of indications with significant market potential. Positive clinical trial results for pepinemab in NSCLC, HNSCC, Huntington's disease, or Alzheimer's disease could serve as major catalysts, driving significant stock appreciation. The development of VX5 for autoimmune disorders represents a secondary growth opportunity. However, the company's negative profit margin of -3436.2% and reliance on future funding introduce substantial financial risks. Investors should closely monitor clinical trial outcomes, regulatory milestones, and the company's cash runway.
Based on FMP financials and quantitative analysis
VCNX Key Highlights
Pepinemab is in Phase 1b/2 clinical trials for multiple indications, including NSCLC, HNSCC, Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma.
- VX5, a human antibody to CXCL13, is in preclinical development for the treatment of MS and other autoimmune disorders.
- The company's gross margin is 100.0%, reflecting its focus on research and development rather than product sales at this stage.
- Vaccinex has a beta of 0.77, indicating lower volatility compared to the overall market.
- The company has a market capitalization of $2.94M, reflecting its status as a small-cap biotechnology firm.
Who Are VCNX's Competitors?
VCNX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BMNDF Biomind Labs Inc. | $0.60 | +0.00% | $46.5M | 44 |
| CAIHF Chia Tai Enterprises International Limited | $1.07 | +0.00% | $258M | 53 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.21% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are VCNX's Key Strengths?
Proprietary antibody technology platform.
- Pepinemab shows promise in multiple indications.
- Experienced management team.
- Focus on unmet medical needs.
What Are VCNX's Weaknesses?
Limited financial resources.
- Dependence on clinical trial outcomes.
- No currently marketed products.
- High cash burn rate.
What Could Drive VCNX Stock Higher?
VCNX catalyst: Release of Phase 2 clinical trial results for pepinemab in Huntington's disease (estimated Q4 2026).
- Initiation of Phase 1 clinical trial for VX5 in multiple sclerosis (estimated Q2 2027).
- Continued enrollment of patients in ongoing clinical trials for pepinemab in various cancer indications.
- Potential for strategic partnerships and licensing agreements with larger pharmaceutical companies.
- Granting of orphan drug designation for pepinemab in specific indications.
What Are the Key Risks for VCNX?
Clinical trial failures for pepinemab or VX5.
- Regulatory delays or rejection of drug candidates.
- Competition from established pharmaceutical companies with greater resources.
- Difficulty in raising capital to fund research and development.
- Dependence on key personnel and intellectual property.
What Are the Growth Opportunities for VCNX?
- Growth opportunity 1: Successful clinical trials and regulatory approval of pepinemab for Huntington's disease represents a significant growth opportunity. The Huntington's disease market is estimated to reach $1.4 billion by 2028, driven by the lack of effective treatments. Positive Phase 2/3 trial results could lead to accelerated approval and Orphan Drug designation, providing market exclusivity and pricing power for Vaccinex.
- Growth opportunity 2: Expansion of pepinemab's clinical development program to include additional cancer indications, such as melanoma and osteosarcoma, could broaden its market potential. The global market for cancer therapeutics is projected to reach $200 billion by 2027. Vaccinex's targeted approach may offer advantages in specific cancer subtypes, creating niche market opportunities.
- Growth opportunity 3: Advancement of VX5 into clinical trials for multiple sclerosis (MS) represents a strategic growth driver. Positive preclinical data and successful Phase 1 trials could attract partnerships with larger pharmaceutical companies.
- Growth opportunity 4: Strategic partnerships and licensing agreements with larger pharmaceutical companies to co-develop and commercialize pepinemab or VX5 could provide significant financial resources and market access. These partnerships could accelerate the development timeline and expand the company's reach into global markets, generating royalty revenues and milestone payments.
- Growth opportunity 5: Expansion into new therapeutic areas, such as other neurodegenerative diseases or autoimmune disorders, could diversify the company's pipeline and reduce its reliance on pepinemab. This could involve in-licensing new drug candidates or developing novel therapeutic approaches based on Vaccinex's existing expertise in antibody engineering and targeted therapies.
What Are VCNX's Competitive Advantages?
- Proprietary antibody technology platform.
- Strong intellectual property protection for pepinemab and VX5.
- Clinical data supporting the efficacy and safety of pepinemab.
- Expertise in targeted biotherapeutics and antibody engineering.
What Does VCNX Do?
Vaccinex, Inc., founded in 2001 and headquartered in Rochester, New York, is a clinical-stage biotechnology company dedicated to discovering and developing targeted biotherapeutics. The company's mission is to address serious diseases and conditions with significant unmet medical needs, focusing on cancer, neurodegenerative diseases, and autoimmune disorders. Vaccinex's lead product candidate, pepinemab, is a humanized monoclonal antibody that has undergone Phase 1b/2 clinical trials for various indications, including non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. The company is also developing VX5, a human antibody to CXCL13, currently in preclinical development for the treatment of multiple sclerosis (MS) and other autoimmune disorders. Vaccinex operates with a team of 23 employees, focusing on research and development to advance its pipeline of therapeutic candidates. The company's strategy involves targeting specific disease pathways to create effective treatments for conditions with limited existing options, positioning itself as an innovator in the biotechnology space.
What Products and Services Does VCNX Offer?
- Develop targeted biotherapeutics for serious diseases.
- Focus on unmet medical needs in cancer, neurodegenerative diseases, and autoimmune disorders.
- Advance pepinemab, a humanized monoclonal antibody, through clinical trials.
- Develop VX5, a human antibody to CXCL13, for autoimmune disorders.
- Conduct preclinical and clinical research to evaluate drug candidates.
- Seek strategic partnerships for co-development and commercialization.
How Does VCNX Make Money?
- Develop and out-license or sell biopharmaceutical assets.
- Generate revenue through licensing agreements and milestone payments.
- Potentially generate revenue through direct sales of approved therapeutics.
- Fund research and development through equity financing and partnerships.
What Industry Does VCNX Operate In?
Vaccinex operates within the highly competitive biotechnology industry, characterized by intense research and development, stringent regulatory requirements, and significant capital needs. The industry is driven by the increasing prevalence of chronic diseases, advancements in genomic technologies, and the demand for personalized medicine. Key trends include the development of novel immunotherapies, gene therapies, and targeted drug delivery systems. Vaccinex's focus on targeted biotherapeutics aligns with these trends, positioning it to potentially capitalize on the growing market for innovative treatments. Competitors range from large pharmaceutical companies to smaller biotech firms, all vying for market share in specific therapeutic areas.
Who Are VCNX's Key Customers?
- Future patients with cancer, neurodegenerative diseases, and autoimmune disorders.
- Potential pharmaceutical partners seeking novel therapeutic candidates.
- Healthcare providers prescribing the company's therapies.
Vaccinex, Inc. (VCNX) Valuation Context
Valued at $2.94M, VCNX is classified as a micro-cap stock. Relative to its peer group, VCNX's quantitative score of 55/100 is below the peer average of 65/100.
VCNX Revenue & Earnings Trend
In Q4 2024, VCNX generated $213K in top-line revenue, marking a sequential increase of 309.6%. The company recorded a net loss of $3.4M, with diluted EPS of $-1.61. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, VCNX averaged $-2.62 in diluted EPS.
Company Profile
Vaccinex, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Rochester, US. The company is led by CEO Maurice Zauderer. VCNX has traded publicly since 2018.
Key Financial Metrics
Return on equity for Vaccinex, Inc. stands at 104.4%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.45 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
Vaccinex, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile.
Earnings Track Record
Vaccinex, Inc. has beaten Wall Street's EPS estimate in 8 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 55.4% above estimates on average.
VCNX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Vaccinex's pipeline, indicating potential positive developments ahead.
- Community sentiment has shifted positively, with discussions highlighting the company's innovative approaches to cancer treatment.
- Recent partnerships and collaborations have enhanced the company's credibility and visibility in the biotech sector.
- Advancements in clinical trials have been well-received, with many optimistic about the outcomes and their impact on stock performance.
Bear Case
- Concerns about the high burn rate and funding challenges could deter investors looking for stability.
- Some community members express skepticism regarding the timeline for product approvals, which may affect investor sentiment.
- Recent regulatory hurdles have raised doubts about the speed at which Vaccinex can bring products to market, impacting future growth projections.
- Market perception remains cautious as competitors in the biotech space continue to make significant strides, overshadowing Vaccinex's progress.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2024 | $213,000 | -$3M | -$1.61 |
| Q3 2024 | $52,000 | -$6M | -$2.83 |
| Q2 2024 | $232,000 | -$6M | -$3.10 |
| Q1 2024 | $104,000 | -$4M | -$2.94 |
Based on FMP financials and quantitative analysis
VCNX Latest News
No recent news available for VCNX.
VCNX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for VCNX.
Price Targets
Wall Street price target analysis for VCNX.
VCNX MoonshotScore
What does this score mean?
The MoonshotScore rates VCNX 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Maurice Zauderer
CEO
Maurice Zauderer is the CEO of Vaccinex, Inc. His background includes extensive experience in the biotechnology industry, with a focus on drug discovery and development. He has been involved in the founding and management of several biotechnology companies. Zauderer's expertise spans various therapeutic areas, including oncology, neurology, and immunology. He has a strong track record of leading research teams and advancing novel therapies through preclinical and clinical development.
Track Record: Under Maurice Zauderer's leadership, Vaccinex has advanced pepinemab into Phase 1b/2 clinical trials for multiple indications, including Huntington's disease and Alzheimer's disease. He has overseen the development of VX5, a human antibody to CXCL13, currently in preclinical development. Zauderer has also secured funding to support the company's research and development efforts. His strategic decisions have focused on targeting unmet medical needs and building a pipeline of innovative biotherapeutics.
VCNX OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Vaccinex may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and operational performance. Investing in companies on the OTC Other tier carries a higher degree of risk compared to those listed on major exchanges like the NYSE or NASDAQ, due to the potential for less transparency and regulatory oversight.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Potential for lower trading volumes and liquidity.
- Higher price volatility compared to stocks on major exchanges.
- Increased risk of fraud or manipulation.
- Limited regulatory oversight.
- Verify the company's financial statements and SEC filings (if available).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent protection.
- Review the company's clinical trial data and regulatory status.
- Consult with a financial advisor before investing.
- Understand the risks associated with investing in OTC stocks.
- Pepinemab is in Phase 1b/2 clinical trials, indicating some level of scientific validation.
- The company has a management team with experience in the biotechnology industry.
- Vaccinex has intellectual property protection for its drug candidates.
- The company is focused on addressing unmet medical needs, which could attract investor interest.
What Investors Ask About Vaccinex, Inc. (VCNX) — Healthcare
What does the AI Score mean for VCNX?
VCNX holds an AI Score of 55/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. Vaccinex, Inc. is a clinical-stage biotechnology company focused on developing targeted biotherapeutics for cancer, neurodegenerative diseases, and autoimmune disorders. Their lead product …
What does Vaccinex, Inc. do?
Vaccinex, Inc. is a clinical-stage biotechnology company focused on developing targeted biotherapeutics to treat serious diseases with unmet medical needs. Their primary focus is on pepinemab, a humanized monoclonal antibody currently in Phase 1b/2 clinical trials for various indications, including Huntington's disease, Alzheimer's disease, and certain cancers.
What do analysts say about VCNX stock?
As of March 15, 2026, there is limited analyst coverage available for Vaccinex, Inc. due to its small market capitalization and clinical-stage status. Key valuation metrics, such as price-to-earnings ratio, are not meaningful due to the company's negative profitability. Growth considerations center around the successful development and commercialization of pepinemab and VX5. Investors should conduct thorough due diligence and consider the inherent risks associated with investing in clinical-stage biotechnology companies.
What are the main risks for VCNX?
The main risks for Vaccinex, Inc. include the inherent uncertainties of clinical trials, potential regulatory hurdles, and intense competition from larger pharmaceutical companies. Clinical trial failures for pepinemab or VX5 could significantly impact the company's value. Securing sufficient funding to support ongoing research and development is also a critical risk. Additionally, the company's reliance on key personnel and intellectual property exposes it to potential disruptions.
What are the key factors to evaluate for VCNX?
Vaccinex, Inc. (VCNX) holds an AI score of 55/100 (moderate). presents a high-risk, high-reward investment profile typical of clinical-stage biotechnology companies. Not financial advice.
How frequently does VCNX data refresh on this page?
VCNX's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven VCNX's recent stock price performance?
Vaccinex, Inc. (VCNX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary antibody technology platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider VCNX overvalued or undervalued right now?
Vaccinex, Inc. (VCNX) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research VCNX before investing?
Before investing in Vaccinex, Inc. (VCNX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited analyst coverage for VCNX.
- OTC market carries higher risks than major exchanges.
- Clinical trial outcomes are uncertain.